Keratosis Clinical Trial
Official title:
Efficacy and Safety of Ultrapulse Carbon Dioxide Laser Treatment in Eyelid Tumors
This study aims to assess the long-term efficacy and safety of ultrapulse carbon dioxide (CO₂) laser excision in the treatment of eyelid tumors, including xanthelasma, pigmented nevi, keratoses, and so on.
-Background: The assessment of the efficacy and safety of Ultrapulse CO₂ laser in treating eyelid lesions is crucial for clinical applications. This study aims to evaluate the effectiveness of super-pulsed CO₂ laser in treating different types of eyelid lesions, particularly marginal and large lesions, to provide comprehensive clinical guidance and decision support. -Main Objectives: A retrospective analysis of the efficacy and safety of Ultrapulse CO₂ laser treatment for various types of eyelid lesions, including xanthelasma, pigmented nevi, keratoses, and so on. -Study Design: This study will include 1000 patients diagnosed with eyelid lesions, including xanthelasma, pigmented nevi, keratoses, and so on. All patients undergoing Ultrapulse CO₂ laser treatment. The evaluation will focus on the efficacy and safety of Ultrapulse CO₂ laser treatment for different types of eyelid lesions. -Study Population and Anticipated Enrollment: Patients with eyelid lesions (n=1000) -Inclusion Criteria: Clinically diagnosed with eyelid lesions, including xanthelasma, pigmented nevi, keratoses, and so on. No history of photosensitivity, bleeding, or coagulation disorders Willing to attend follow-up appointments as scheduled -Exclusion Criteria: Presence of infection in the target area Allergy to lidocaine Keloid-prone or poor skin repair ability Pregnant or lactating Recent history of severe infectious diseases, active skin diseases, or major diseases affecting the cardiovascular, liver, kidney, endocrine, and hematopoietic systems History of malignant tumors or immune system disorders ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00239135 -
Study to Determine the Maximum Tolerated Dose and Safety of PEP005 Topical Gel
|
Phase 2 | |
| Completed |
NCT00115154 -
Study to Assess the Safety and Efficacy of Imiquimod 5% Cream for the Treatment of Actinic Keratosis on the Arms and Hands
|
Phase 4 | |
| Recruiting |
NCT04336514 -
A Longitudinal Quantitative Assessment of the Effectiveness of Metatarsal Pads on Plantar Pressures
|
N/A | |
| Completed |
NCT00116649 -
Open-Label Safety Study to Evaluate Imiquimod Cream, 5% for Large Areas of Actinic Keratosis
|
Phase 4 | |
| Recruiting |
NCT05942794 -
Identification of Oral Lesions Through an Autofluorescence System
|
N/A | |
| Withdrawn |
NCT02851693 -
Study of Imaging Characteristics OCT of Skin Lesions Requiring Biopsy / Resection
|
N/A | |
| Withdrawn |
NCT02813902 -
A Trial of Polypodium Leucotomos in Preventing Skin Cancer and Its Precursors
|
Phase 1 | |
| Completed |
NCT00121511 -
The Effect of Efudex Treatment on Photoaged Skin
|
N/A | |
| Completed |
NCT00114023 -
1-Year Follow up to the 1473-IMIQ Study
|
Phase 3 | |
| Completed |
NCT05060237 -
Study to Evaluate Safety and Tolerability of BF-200 ALA (Ameluz®) for Photodynamic Therapy in the Treatment of the Expanded Field of Actinic Keratosis on Face and Scalp
|
Phase 1 | |
| Recruiting |
NCT02737176 -
Tobacco Cessation Intervention Study for Oral Diseases
|
N/A | |
| Completed |
NCT00110682 -
Study of Imiquimod 5% Cream in Addition to Cryotherapy in the Management of Actinic Keratoses
|
Phase 4 |